To explore NOLC1’s potential role in the sensitization of melanoma cells to MEK inhibitors (MEKis), we downregulated NOLC1 by shRNA and treated two cell lines, A375 and WM983B, with increasing concentrations of trametinib, a clinically approved drug for advanced melanoma treatment. The gene discussed is MAP2K7; the disease is melanoma.